Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 10, 2009, Pages 1409-1416

  Saravia, Mario ^a   Zapata, Gustavo ^a   Ferraiolo, Paula ^a   Racca, Lourdes ^a   Berra, Alejandro ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Bevacizumab; Herpes; Keratitis; VEGF

Indexed keywords

BEVACIZUMAB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA VASCULARIZATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL RABBIT; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CICATRIX; CONJUNCTIVA; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; DISEASE PROGRESSION; INJECTIONS; KERATITIS, HERPETIC; NEUTROPHIL INFILTRATION; RABBITS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

EID: 69549116461     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1101-y     Document Type: Article

References (41)

1. Wagner EK, Bloom DC (1997) Experimental investigation of herpes simplex virus latency. Clin Microbiol Rev 10(3):419-443
2. Carr DJ, Harle P, Gebhardt BM (2001) The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med (Maywood) 226(5):353-366
3. Biswas PS, Rouse BT (2005) Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect 7(4):799-810
4. Cursiefen C et al (2006) Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25(4):443-447. doi: 10.1097/01.ico.0000183485.85636.ff
5. Dana MR (2006) Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol 21(1):19-22. doi: 10.1080/ 08820530500509358
6. Heiligenhaus A et al (1999) CD4+ T-cell type 1 and type 2 cytokines in the HSV-1 infected cornea. Graefes Arch Clin Exp Ophthalmol 237(5):399-406. doi: 10.1007/s004170050251
7. Duan R et al (2007) Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: Implications for the role of neutrophils in HSK. Invest Ophthalmol Vis Sci 48(1):277-284. doi: 10.1167/iovs.06-0053
8. Lee S et al (2002) Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 110(8):1105-1111
9. Biswas PS et al (2006) Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res 82(1):46-54. doi: 10.1016/ j.exer.2005.05.001
10. Biswas PS et al (2004) Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. J Leukoc Biol 76(4):868-875. doi: 10.1189/jlb.0504280
11. Zheng M et al (2001) Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75(20):9828-9835. doi: 10.1128/ JVI.75.20.9828-9835.2001
12. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342. doi: 10.1056/NEJMoa032691
13. Scott IU et al (2008) Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina 28(1):36-40. doi: 10.1097/IAE.0b013e31815e9313
14. Bashshur ZF et al (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 145(2):249-256. doi: 10.1016/j.ajo.2007.09.031
15. Bahar I et al (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(2):142-147. doi: 10.1097/ ICO.0b013e318159019f
16. Bahar I et al (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33(1):23-28. doi: 10.1080/02713680701799101
17. Chen WL, et al Subconjunctival injection of bevacizumab (Avastin) inhibits corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci, 2008
18. Asbell PA (2000) Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy. Trans Am Ophthalmol Soc 98:285-303
19. Azkur AK et al (2005) Blocking mouse MMP-9 production in tumor cells and mouse cornea by short hairpin (sh) RNA encoding plasmids. Oligonucleotides 15(2):72-84. doi: 10.1089/oli.2005.15.72
20. Rong BL et al (1991) Detection of herpes simplex virus thymidine kinase and latency-associated transcript gene sequences in human herpetic corneas by polymerase chain reaction amplification. Invest Ophthalmol Vis Sci 32(6):1808-1815
21. Gangappa S et al (1998) Virus-induced immunoinflammatory lesions in the absence of viral antigen recognition. J Immunol 161(8):4289-4300
22. Dana MR, Zhu SN, Yamada J (1998) Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea 17(4):403-409. doi: 10.1097/00003226-199807000-00011
23. Cursiefen C et al (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113(7):1040-1050
24. Liesegang TJ et al (1989) Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 107(8):1155-1159
25. Zheng M et al (2001) Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 159(3):1021-1029
26. Simon HU (2003) Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev 193:101-110. doi: 10.1034/ j.1600-065X.2003.00038.x
27. D'Amato RJ et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082-4085. doi: 10.1073/pnas.91.9.4082
28. Chang JH et al (2001) Corneal neovascularization. Curr Opin Ophthalmol 12(4):242-249. doi: 10.1097/00055735-200108000-00002
29. Haynes WL, Proia AD, Klintworth GK (1989) Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 30(7):1588-1593
30. Rugo HS (2004) Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 9(Suppl 1):43-49. doi: 10.1634/ theoncologist.9-suppl_1-43
31. Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol 33(5)(Suppl 10):S26-S34. doi: 10.1053/ j.seminoncol.2006.08.001
32. Dana R (2007) Comparison of topical interleukin-1 vs. tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 105:330-43
33. Carrasco MA (2008) Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 27(6):743-745
34. Doctor PP, Bhat PV, Foster CS (2008) Subconjunctival bevacizumab for corneal neovascularization. Cornea 27(9):992-995. doi: 10.1097/ ICO.0b013e31817786ad
35. Han YS, et al Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol, 2008
36. Hurmeric V et al (2008) Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 27(3):357-362. doi: 10.1097/ICO.0b013e318160d019
37. Kim TI et al (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27(3):349-352. doi: 10.1097/ICO.0b013e31815cf67d
38. Qian CX et al (2008) Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(9):1090-1092. doi: 10.1097/ICO.0b013e31817c41e3
39. Remeijer L, Osterhaus A, Verjans G (2004) Human herpes simplex virus keratitis: The pathogenesis revisited. Ocul Immunol Inflamm 12(4):255-285. doi: 10.1080/092739490500363
40. Barros LF, Belfort R Jr (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79(3):389-394. doi: 10.1590/S0001-37652007000300004
41. Yoeruek E et al (2007) Safety profile of bevacizumab on cultured human corneal cells. Cornea 26(8):977-982. doi: 10.1097/ICO.0b013e3180de1d0a